STOCK TITAN

Co-Diagnostics Receives Logix Smart® ZDC Test Order from Peru Distributor as Dengue Cases Rise and Exhibits at MEDICA 2026 in Düsseldorf

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Co-Diagnostics (Nasdaq: CODX) received a new Logix Smart ZDC test order from its Peru distributor amid rising dengue activity. It also shipped tests purchased by a European organization for a study with a laboratory in Bolivia. Approximately 17 real-time PCR instruments have been shipped to its Bolivia distributor since the beginning of 2025.

The ZDC test detects and differentiates Zika, dengue and chikungunya. It has been CE-IVD marked since 2019 and is available in markets accepting that marking, but not for sale in the United States. Co-Diagnostics is exhibiting at MEDICA 2026, November 16–19, in Düsseldorf, meeting international customers and distributors.

Loading...
Loading translation...

Positive

  • Minor pointPeru distributor placed a new Logix Smart ZDC test order amid rising dengue activity.
  • Minor pointPurchased ZDC tests shipped for a European organization's study with a laboratory in Bolivia.
  • Minor pointBolivia distributor received approximately 17 real-time PCR instruments since the beginning of 2025.

Negative

  • Minor pointLogix Smart ZDC is not available for sale in the United States.
Argus 15 min delay 3 alerts
-8.67% vs previous close $0.2054 last price 10.4x rel. volume Open Argus
Details

Market Reaction – CODX

$0.20 – $0.21 Day Range
$2.16M Mkt Cap at Last Price

On Nov 17, the day this news came out, the latest delayed price for CODX is 8.67% below the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $0.21. Relative volume is exceptionally heavy at 10.4x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Dengue cases: 83,430 cases Weekly dengue case change: 51% PCR instruments shipped: Approximately 17 units
Dengue cases
83,430 cases
Peru, 2026 through epidemiological week 42
Weekly dengue case change
51%
Week 42 compared with the average of the previous four weeks
PCR instruments shipped
Approximately 17 units
To the Bolivia distributor since the beginning of 2025

Key Terms

real-time rt-pcr, ce-ivd, multiplex
3 terms
real-time rt-pcr technical
"a real-time RT-PCR test that uses the Company's patented"
A laboratory method that detects and measures specific RNA sequences by first converting RNA into DNA (reverse transcription, RT) and then amplifying that DNA while monitoring the amplification as it happens (real-time PCR). Fluorescent markers produce a signal during each amplification cycle, allowing technicians to determine whether the target RNA is present and to estimate its amount based on how many cycles are required to reach a detectable signal; it detects nucleic acid, not whether material is infectious or viable.
ce-ivd regulatory
"available for sale in the European Union and other markets that accept CE-IVD marking"
CE‑IVD is the European conformity mark showing that an in vitro diagnostic device — a medical test used on samples like blood or tissue — meets the EU’s safety and performance requirements for sale. For investors, it’s like a stamped passport that opens access to EU markets, signaling lower regulatory risk, broader commercial potential, and a clearer path to revenue for companies that make diagnostic tests.
multiplex technical
"the need for a multiplex CE-IVD marked assay"
A multiplex is a laboratory test or diagnostic method that detects or measures several different targets at the same time from a single sample, like checking for multiple ingredients in one recipe rather than cooking separate dishes. For investors, multiplex technologies can lower testing costs, speed results, and expand market reach because one product can serve multiple purposes, affecting revenue potential, production scale, and regulatory review paths.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Company Also Ships Logix Smart ZDC Tests for Study in Bolivia

Co-Dx to Meet with International Customers and Distributors at World Trade Center Utah Booth

SALT LAKE CITY, Nov. 17, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that its distributor in Peru has placed a new order for its Logix Smart® ZDC (ZIKV-DENV-CHIKV) test as the country experiences a rise in dengue activity, and shipped Logix Smart® ZDC tests purchased by a European organization for use in a study in Bolivia. The Company is also exhibiting at MEDICA 2026, taking place November 16–19 in Düsseldorf, Germany.

In Peru, the Company's distributor recently placed a new order for the Logix Smart ZDC test as the country experiences a rise in dengue activity. According to the Pan American Health Organization (PAHO), Peru has reported 83,430 dengue cases in 2026 through epidemiological week 42, and cases reported that week were up 51% compared with the average of the previous four weeks.

In Bolivia, the tests were purchased by a European organization for a study in collaboration with a prominent laboratory in Bolivia. Co-Dx also continues to supply real-time PCR instruments to its distributor in Bolivia, with approximately 17 units shipped since the beginning of 2025.

The Logix Smart ZDC test is a real-time RT-PCR test that uses the Company's patented Co-Primers® technology to detect and differentiate between Zika, dengue and chikungunya viruses, which are spread by mosquitoes and often present with similar symptoms. The test has been CE-IVD marked since 2019 and is available for sale in the European Union and other markets that accept CE-IVD marking. It is not available for sale in the United States. 

"New orders for our Logix Smart ZDC test in South America reflect the need for a multiplex CE-IVD marked assay that detects and differentiates Zika, dengue and chikungunya," said Dwight Egan, Chief Executive Officer of Co-Diagnostics. "These orders put our technology to work in regions where these mosquito-borne diseases are a public health concern. MEDICA gives our team direct access to the customers and distributors who drive our international business, and we are in Düsseldorf this week to build those relationships." 

Co-Dx is exhibiting at MEDICA 2026 as part of the World Trade Center Utah booth at Stand 16E24-1 in Hall 16. MEDICA is one of the world's largest trade fairs for medical technology and healthcare, drawing international exhibitors across diagnostics, laboratory equipment and health IT. Co-Dx has exhibited at MEDICA several times, and the event is a key meeting point with customers and distributors from South Asia and the Middle East, two of the Company's main target markets.

"Success in global business comes to those who show up," said World Trade Center Utah," said Jonathan Freedman, President and CEO of World Trade Center Utah. "International trade shows like MEDICA put companies face-to-face with the customers, distributors and partners who can drive their next stage of growth. At World Trade Center Utah, we help businesses like Co-Diagnostics make those connections and turn global opportunities into business results. We're excited to see what comes from their participation at MEDICA and the relationships they build along the way."

Co-Dx is also hosting two webinars today: one for potential customers of its Vector Smart™ mosquito surveillance solutions, and one through CoSara Diagnostics, the Company's joint venture in India, on HPV and cervical cancer screening in recognition of World Cervical Cancer Elimination Day. For more information about either webinar, please contact info@co-dx.com.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will," "seeks," "anticipates," and similar expressions, or the negative of these terms. Forward-looking statements in this press release include, but are not limited to, the Company's participation in MEDICA 2026 and its ability to engage customers and distributors in its target markets; the use of the Logix Smart ZDC test in a study in Bolivia; the Company's ability to generate additional orders for the Logix Smart ZDC test and its other products in South America and other markets; the Company's continued supply of real-time PCR instruments to its distributor in Bolivia; the Company's ability to support laboratories in regions where Zika, dengue and chikungunya are a public health concern; and the Company's planned webinars. Such statements are subject to a number of risks and uncertainties, including, without limitation: risks that market demand or public health conditions may change; risks that epidemiological data referenced in this press release are preliminary and subject to revision; risks that participation in trade fairs or webinars may not result in new customers, distribution relationships or sales; risks that orders from distributors or other purchasers may not recur or may be reduced; risks that the study in Bolivia may not be completed as planned or may not lead to additional orders; risks that distribution partners may not successfully market, promote, or sell the Company's or its joint venture's products; risks associated with international operations, including changing regulatory requirements, economic conditions, reimbursement environments, import/export restrictions, and foreign currency fluctuations; risks related to maintaining CE-IVD marking and other regulatory authorizations for the Company's products, including under evolving European regulatory requirements; risks related to the performance, reliability, and market acceptance of the Logix Smart and Vector Smart product lines and other Co-Dx technologies; risks associated with dependence on third parties, suppliers, collaborators, and distribution partners; risks related to competition, technological change, and intellectual property protection; and other risks described from time to time in the Company's filings with the Securities and Exchange Commission ("SEC"). Actual results may differ materially from those expressed or implied in these forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. A further description of risks and uncertainties can be found in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2026, and in its other filings with the SEC. The Company undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release, except as required by applicable law.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-receives-logix-smart-zdc-test-order-from-peru-distributor-as-dengue-cases-rise-and-exhibits-at-medica-2026-in-dusseldorf-302942000.html

SOURCE Co-Diagnostics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What new South American orders and shipments did Co-Diagnostics announce for CODX?

Co-Diagnostics received a new Logix Smart ZDC order from its Peru distributor and shipped tests purchased by a European organization for a study in Bolivia. The study involves collaboration with a laboratory in Bolivia.

Keep reading